Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$9.49 USD
-0.22 (-2.27%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $9.50 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARQT 9.49 -0.22(-2.27%)
Will ARQT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Other News for ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
Morgan Stanley Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Strong Zoryve Launch Prospects